Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

The Associated Press August 25, 2010, 2:20PM ET

Neuralstem asks FDA to clear stem cell study

Neuralstem has asked the Food and Drug Administration to approve an early-stage safety study on a potential spinal cord injury treatment, the company said Wednesday.

The treatment was developed using adult stem-cell technology, specifically with stem cells taken from the spinal cord.

Shares of Neuralstem Inc. rose 20 cents, or 11.1 percent, to $2 in afternoon trading. The stock has traded between $1.04 and $3.49 over the last 52 weeks.

BW Mall - Sponsored Links

Buy a link now!